The Annual General Meeting of Nobel Biocare approves all proposals of the Board of Directors
Among others, the Annual General Meeting approved a dividend of CHF 0.15 gross per registered share of CHF 0.40 nominal value. The dividend will be paid on 5 April 2012 (ex-dividend day: 2 April 2012; record date: 4 April 2012) in a shareholder-friendly way without deduction of withholding tax.
The Board members proposed for re-election were re-elected: Daniela Bosshardt-Hengartner, Raymund Breu, Edgar Fluri, Oern Stuge and Rolf Watter.
Michel Orsinger, Juha Räisänen and Georg Watzek were elected as new Board members.
According to the by-laws, all Board members have been elected for a one-year term.
At the first Board meeting following the Annual General Meeting, Rolf Watter was elected Chairman of the Board and Raymund Breu was elected Vice-Chairman of the Board. The Board committees will be chaired by Michel Orsinger (Innovation and Technology), Edgar Fluri (Audit) and Rolf Watter (Nomination and Compensation).
KPMG, Zurich, has been re-elected as auditor for the financial year 2012.
In 2013, the Annual General Meeting of the shareholders will be convened on 28 March at the same location (Swissôtel Zurich).
This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.
NOBEL BIOCARE MANAGEMENT AG
Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative restorative and esthetic dental solutions. As a complete solutions provider, Nobel Biocare offers the most comprehensive range of solutions from tooth-to-root, for single tooth to edentulous indications. The solutions portfolio covers dental implants (including the key brands NobelActiveTM, Brånemark System® and NobelReplaceTM) as well as individualized prosthetics and equipment (NobelProceraTM guided surgery solutions and biomaterials). Nobel Biocare has more than 2,400 employees and recorded revenue of EUR 569.2 million in 2011. The company is headquartered in Zurich, Switzerland. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the US. Nobel Biocare has 34 direct sales organizations.